The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...

Q Genetics secured investment from K-Ground Partners' IP Fund, giving impetus to its new drug development endeavors. Subsequent to the completion of its Phase 1 trial, t ...

Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of the drug is set to continue. Announced in the company’s Q4 earnings call, ...

During a health-focused event in New York on Tuesday, Google announced the development of a new collection of “open” AI ...